{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:07:33Z","timestamp":1791439653628,"version":"4.3.3"},"reference-count":32,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["grant number 199-0386"],"award-info":[{"award-number":["grant number 199-0386"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,2,9]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Owing to discrepancies in methodologies and how idiopathic pulmonary fibrosis (IPF) is diagnosed it is challenging to establish a consistent understanding of the disease burden In the UK, over 10 years ago, the incidence and prevalence of IPF were reported as 2.8\u20138.7 per 100\u2009000 person-years (from 2000 to 2012) and 39 per 100\u2009000 persons (in 2012), respectively. Here, we estimated the incidence and prevalence of IPF in England from 2008 to 2018 and investigated IPF mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using Clinical Practice Research Datalink Aurum and Hospital Episode Statistics (HES) linked datasets, we estimated incidence and prevalence using four validated diagnostic-code-based algorithms. Using the registered number of deaths (from Office of National Statistics) with the underlying cause being recorded as IPF, we estimated IPF mortality for the same period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using Aurum-based definitions, incidence increased over time by 100% for Aurum narrow (3\u20136.1 per 100\u2009000 person-years) and by 25% for Aurum broad (22.4\u201328.6 per 100\u2009000 person-years). However, using HES-based definitions showed a decrease in incidence over the same period and lay between the two extremes derived for Aurum-based definition. IPF mortality in 2018 was 7.9 per 100\u2009000 person-years and increased by 53% between 2008 and 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>When using best-case definitions, incidence rose throughout the study period. Scaling this to England\u2019s population (2018), our best estimate would be in the range of 8000\u20139000 new cases per year which is higher than previously reported estimates (5000\u20136000). This increased burden in the new cases of IPF each year impacts future health service planning and resource allocation.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thorax-2023-220887","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:29:10Z","timestamp":1714498150000},"page":"624-631","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in England from 2008 to 2018: a cohort study"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9784-416X","authenticated-orcid":false,"given":"Rikisha","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4794-0860","authenticated-orcid":false,"given":"Ann Dorothy","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-4891","authenticated-orcid":false,"given":"Peter M","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4869","authenticated-orcid":false,"given":"Jennifer K","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"2025012402150638000_79.7.624.1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025012402150638000_79.7.624.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705751"},{"key":"2025012402150638000_79.7.624.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001291","article-title":"Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review","volume":"10","author":"Shah Gupta","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2025012402150638000_79.7.624.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"key":"2025012402150638000_79.7.624.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00185114"},{"key":"2025012402150638000_79.7.624.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025012402150638000_79.7.624.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2025012402150638000_79.7.624.8","unstructured":"National Institute for Health and Care Excellence . Idiopathic pulmonary fibrosis in adults: diagnosis and management. London: NICE, 2013. Available: https:\/\/www.nice.org.uk\/guidance\/cg163"},{"key":"2025012402150638000_79.7.624.9","unstructured":"National Institute for Health and Care Excellence . Pirfenidone for treating idiopathic pulmonary fibrosis (technology appraisal guidance [TA504]). London: NICE, 2018. Available: https:\/\/www.nice.org.uk\/guidance\/ta504"},{"key":"2025012402150638000_79.7.624.10","unstructured":"National Institute for Health and Care Excellence . Nintedanib for treating idiopathic pulmonary fibrosis technology appraisal guidance [TA379]). London: NICE, 2016. Available: https:\/\/www.nice.org.uk\/guidance\/ta379"},{"key":"2025012402150638000_79.7.624.11","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0217OC"},{"key":"2025012402150638000_79.7.624.12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2B trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025012402150638000_79.7.624.13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with Unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025012402150638000_79.7.624.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025012402150638000_79.7.624.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0693-1"},{"key":"2025012402150638000_79.7.624.16","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.148031"},{"key":"2025012402150638000_79.7.624.17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1164\/rccm.201902-0467LE","article-title":"The mortality burden of idiopathic pulmonary fibrosis in the United Kingdom","volume":"200","author":"Navaratnam","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025012402150638000_79.7.624.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-023-02550-0","article-title":"Validation of the recording of idiopathic pulmonary fibrosis in routinely collected electronic healthcare records in England","volume":"23","author":"Morgan","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2025012402150638000_79.7.624.19","unstructured":"Clinical Practice Research Datalink . Latest linked datasets. retrieved from CPRD UK data driving real-world evidence. n.d. Available: https:\/\/cprd.com\/latest-linked-datasets"},{"key":"2025012402150638000_79.7.624.20","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2025012402150638000_79.7.624.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0442-4"},{"key":"2025012402150638000_79.7.624.22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx015"},{"key":"2025012402150638000_79.7.624.23","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4747"},{"key":"2025012402150638000_79.7.624.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.04.011"},{"key":"2025012402150638000_79.7.624.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2025012402150638000_79.7.624.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2025012402150638000_79.7.624.27","unstructured":"Office for National Statistics . Population estimates for the UK, England and Wales. Scotland and Northern Ireland. 2019. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/mid2019estimates [Accessed 1 Aug 2023]."},{"key":"2025012402150638000_79.7.624.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"2025012402150638000_79.7.624.29","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X483562"},{"key":"2025012402150638000_79.7.624.30","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101050","article-title":"GP coding behaviour for non-specific clinical presentations: a pilot study","volume":"4","author":"Tulloch","year":"2020","journal-title":"BJGP Open"},{"key":"2025012402150638000_79.7.624.31","doi-asserted-by":"publisher","DOI":"10.1136\/thx.46.8.589"},{"key":"2025012402150638000_79.7.624.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005540","article-title":"Validation of chronic obstructive pulmonary disease recording in the clinical practice research datalink (CPRD-GOLD)","volume":"4","author":"Quint","year":"2014","journal-title":"BMJ Open"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-220887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T10:17:31Z","timestamp":1737713851000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-220887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,6,14]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/thorax-2023-220887"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-220887","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]}}}